Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: Latest results

European Heart Journal, Supplement

Volumn 5, Issue E, 2003, Pages

  Pannier, B ^a   Guerin A P ^a   Marchais, S J ^a   London, Gérard M ^a  

^a Hopital FH Manhes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG EFFECT; ENZYME INHIBITION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PULSE WAVE; RISK BENEFIT ANALYSIS;

EID: 10744227165     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90028-9     Document Type: Conference Paper

References (29)

1. USRD. Causes of death. United States Renal Data System. Am J Kidney Dis 1998;32(suppl 1):S81-8.
2. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54.
3. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 2000;14:898-902.
4. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1992;47:186-92.
5. Silberberg J, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-90.
6. London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 1997;4:194-211.
7. London GM, Marchais SJ, Guérin AP, Fabiani F, Métivier F. Cardiovascular function in hemodialysis patients. In: Grünfeld JP, Bach JF, Funck-Brentano JL, Maxwell MH, eds. Advances in Nephrology, vol. 20. St Louis: Mosby-Year Book, 1991:249-73.
8. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
9. Ozkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998;13:1489-93.
10. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001;38:371-6.
11. Ahearn DJ, Maher JF. Heart failure as a complication of hemodialysis fistula. Ann Intern Med 1972;70:201-4.
12. Rosenthal DS, Braunwald E. Hematological-oncological disorders and heart disease. In: Braunwald E, ed. Heart Disease: Textbook of Cardiovascular Medicine, 4th Edition. Philadelphia: Saunders, 1992:1786-808.
13. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
14. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990;6:1-4.
15. Portoles J, Torralbo A, Martin P, Rodrigo R, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in pre-dialysis patients. Am J Kidney Dis 1997;29:541-8.
16. London GM, Guérin AP, Pannier B, Marchais SJ, Benetos A, Safar ME. Increased systolic pressure in chronic uremia: role of arterial wave reflections. Hypertension 1992;20:10-9.
17. Klassen P, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002;287:1548-55.
18. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002;61:717-26.
19. Nichols WW, O'Rourke MF. Vascular impedance. In: McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, 4th Edition. London: Edward Arnold, 1998:243-83.
20. London GM, Marchais SJ, Safar ME, et al. Aortic and large artery compliance in end-stage renal disease. Kidney Int 1990;37:137-42.
21. London GM, Guérin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
22. Matsumoto Y, Hamada M, Hiwada K. Aortic distensibility is closely related to the progression of left ventricular hypertrophy in patients receiving hemodialysis. Angiology 2000;51:933-41.
23. Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME, London GM. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998;32:570-4.
24. Blacher J, Guérin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
25. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.
26. Guérin AP, London GM, Marchais SJ, Métivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
27. London GM, Pannier B, Guérin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-67.
28. London GM, Pannier B, Guérin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994;90:2786-96.
29. Guérin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92.